Validation of a Stability-Indicating Analytical Method Development for Simultaneous Estimation of Sodium Phenylbutyrate and Taurursodiol in Bulk and Formulation Using UPLC Method Analytical Method Development for Simultaneous Estimation of SPB and TRS in Bulk and Formulation by UPLC
Iranian Journal of Pharmaceutical Sciences,
Vol. 21 No. 1 (2025),
21 January 2025
,
Page 70- 81
https://doi.org/10.22037/ijps.v21i1.45528
Abstract
Sodium phenylbutyrate (SPB) and taurursodiol (TRS) are commonly used in combination therapy to treat amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease. Using Ultra-Performance Liquid Chromatography, a stability-indicating analytical approach was designed and validated to evaluate SPB and TRS in bulk and dosage form simultaneously. Acquity UPLC BEH Shield RP-18 column (50 x 1.0 mm, 1.7µm) was used for the chromatographic separation. Next, a mobile phase was added at a 0.5 ml/min flow rate. The mobile phase included acetonitrile and 0.1% perchloric acid (20:80) v/v. Analytes were found at a wavelength of 287 nm with a photodiode array detector. An autosampler injected a five μl sample into the column, which was kept at 25 o C. SPB and TRS eluted values were 0.522 min and 1.311 min, respectively. For SPB and TRS, linearity was determined within the range of 75–450 μg/ml and 25–150 μg/ml, respectively. The method's robustness was evaluated by purposefully changing parameters like flow rate, detector wavelength, and column temperature. Additionally, research on forced degradation in the presence of different stress conditions, such as heat, peroxide, acid, and ultraviolet light, showed that the approach could identify stable materials. In conclusion, it was found that the developed analytical method for simultaneously determining SPB and TRS in bulk and their formulation was more precise, reliable, and specific.
- Amyotrophic lateral sclerosis
- Lou Gehrig’s disease
- sodium phenylbutyrate
- taurursodiol
- ultra-performance liquid chromatography
How to Cite
References
Paganoni, Sabrina et al. “Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.” The New England journal of medicine (2020) 383 (10): 919-930. doi:10.1056/NEJMoa1916945
Alqallaf A, Cates DW, Render KP, Patel KA. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. Ann Pharmacother. (2024);58(2):165-173. doi: 10.1177/10600280231172802.
Brotman RG, Moreno-Escobar MC, Joseph J, Munakomi S, Pawar G. Amyotrophic Lateral Sclerosis. (2024) 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. (2020);27(10):1918-1929. doi: 10.1111/ene.14393.
Doble A. The pharmacology and mechanism of action of riluzole. Neurology. (1996) 47(6 Suppl 4): S233-41. doi: 10.1212/wnl.47.6_suppl_4.233s.
Saitoh Y, Takahashi Y. Riluzole for the treatment of amyotrophic lateral sclerosis. Neurodegener Dis Manag. (2020);10(6):343-355. doi: 10.2217/nmt-2020-0033.
Cruz, Martin Paspe. “Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis.” P & T: a peer-reviewed journal for formulary management (2018) 43,1: 25-28.
Beludari, Mahammad I, et al., Development and validation of a stability-indicating analytical method for simultaneous determination of sodium phenylbutyrate and taurursodiol in bulk and formulation using reverse phase ultra-performance liquid chromatography Egyptian Pharmaceutical Journal (2024) 23(2): 264-271. DOI: 10.4103/epj.epj_295_23
Bakshi M, Singh B, Singh A, Singh S; International Conference on Harmonization. The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stability-indicating assay. J Pharm Biomed Anal. (2001);26(5-6):891-7. doi: 10.1016/s0731-7085(01)00475-7.
Blessy, M et al. “Development of forced degradation and stability indicating studies of drugs-A review.” Journal of pharmaceutical analysis vol. 4,3 (2014): 159-165. doi: 10.1016/j.jpha.2013.09.003
Zelesky T, et al., Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. J Pharm Sci. (2023);112(12):2948-2964. doi: 10.1016/j.xphs.2023.09.003.
Dhiman V, Balhara A, Singh S, Tiwari S, Gananadhamu S, Talluri MVNK. Characterization of stress degradation products of nintedanib by UPLC, UHPLC-Q-TOF/MS/MS and NMR: Evidence of a degradation product with a structure alert for mutagenicity. J Pharm Biomed Anal. (2021) 30; 199:114037. doi: 10.1016/j.jpba.2021.114037.
Saha M, Bali A, Patra SR, Singh J. Identification and characterization of stress degradation products of febuxostat employing ultra-performance liquid chromatography-ultraviolet/photodiode array and liquid chromatography-mass spectrometry/time-of-flight studies. Rapid Commun Mass Spectrom. (2023)30;37(2): e9423. doi: 10.1002/rcm.9423.
Kumar A, Saini G, Nair A, Sharma R. UPLC: a preeminent technique in pharmaceutical analysis. Acta Pol Pharm. (2012);69(3):371-80.
Yarra, U.S.T., Gummadi, S. Stability indicating RP-UPLC method for simultaneous quantification of bempedoic acid and ezetimibe in bulk and pharmaceutical formulations. Futur J Pharm Sci (2021) 7, 209. https://doi.org/10.1186/s43094-021-00363-8.
Roy C, Chakrabarty J, Modi PB. Validated Stability-indicating Reverse-phase Ultra-performance Liquid Chromatography Method for Simultaneous Determination of Sodium Methylparaben, Sodium Propylparaben and Ketorolac Tromethamine in Topical Dosage Forms. Indian J Pharm Sci. (2013);75(2):197-204.
Devi, D.A., Bhavani, P.G. Development and validation of stability indicating UPLC method for the simultaneous estimation of triamterene and hydrochlorothiazide in combined dosage forms using quality by design approach. Futur J Pharm Sci (2023); 9, 9. https://doi.org/10.1186/s43094-022-00438-0
Vamsi Dadi, G. Sowjanya. Development and validation of UPLC method for simultaneous estimation of Darunavir, Cobicistat, Emtricitabine and Tenofovir alafenamide in bulk drug and pharmaceutical dosage form. Research Journal of Pharmacy and Technology (2023); 16(5):2336-2. doi: 10.52711/0974-360X.2023.00384
Ibrahim, A., Wang, F., Gary Hollenbeck, R., Martinez, M. N., Fahmy, R., & Hoag, S. W. Development and Validation of a Stability-indicating UPLC-DAD Method for the Simultaneous Determination of Ivermectin and Praziquantel in Pharmaceutical Tablets and Dissolution Media. AAPS PharmSciTech, (2023); 24(7), 211. https://doi.org/10.1208/s12249-023-02656-y
Bhattacharya, K., Mathew, J. Development and validation of stability-indicating UPLC method for the determination of gliclazide and its impurities in pharmaceutical dosage forms. Futur J Pharm Sci 7, 95 (2021). https://doi.org/10.1186/s43094-021-00248-w.
Kumar, Navneet et al. “Development and validation of a UPLC method for the determination of duloxetine hydrochloride residues on pharmaceutical manufacturing equipment surfaces.” Pharmaceutical methods vol. 2,3 (2011): 161-6. doi:10.4103/2229-4708.90355
Narikimalli, A., Galla, R. A stability indicating UPLC method development and validation for the simultaneous estimation of nateglinide and metformin hydrochloride in bulk and tablet dosage form. Futur J Pharm Sci (2023); 9, 55. https://doi.org/10.1186/s43094-023-00503-2.
Reddy, Yarram Ramakoti et al. “RP-UPLC method development and validation for the simultaneous estimation of ibuprofen and famotidine in pharmaceutical dosage form.” Pharmaceutical methods vol. 3,2 (2012): 57-61. doi:10.4103/2229-4708.103873.
Murthy, M Vishnu et al. “Development and validation of RP-UPLC method for the determination of darifenacin hydrobromide, its related compounds and its degradation products using design of experiments.” Journal of pharmaceutical and biomedical analysis vol. (2013); 72: 40-50. doi:10.1016/j.jpba.2012.09.013.
- Abstract Viewed: 474 times
- IJPS_Volume21_Issue1_Pages70-81 Downloaded: 491 times